208 related articles for article (PubMed ID: 24028617)
1. Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats.
Chen Y; Zhang W; Li D; Ai J; Meng Y; Ying X; Kang T
J Pharm Pharmacol; 2013 Oct; 65(10):1500-7. PubMed ID: 24028617
[TBL] [Abstract][Full Text] [Related]
2. Hepatic, gastric, and intestinal first-pass effects of vitexin in rats.
Xue HF; Ying ZM; Zhang WJ; Meng YH; Ying XX; Kang TG
Pharm Biol; 2014 Aug; 52(8):967-71. PubMed ID: 24555505
[TBL] [Abstract][Full Text] [Related]
3. LC determination and pharmacokinetic study of vitexin-4″-O-glucoside in rat plasma after oral administration.
Liu X; Wang D; Zhang W; Wang N; Wang S; Li H; Ying X; Kang T
Nat Prod Res; 2012; 26(10):962-7. PubMed ID: 21834625
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of vitexin-4″-O-glucoside in rats after intravenous application.
Ying XX; Wang F; Cheng ZZ; Zhang WJ; Li HB; Du Y; Liu X; Wang SY; Kang TG
Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):109-15. PubMed ID: 22058050
[TBL] [Abstract][Full Text] [Related]
6. Hepatic, gastric and intestinal first-pass effects of vitexin-2''-O-rhamnoside in rats by ultra-high-performance liquid chromatography.
Gao Y; Du Y; Ying Z; Leng A; Zhang W; Meng Y; Li C; Xu L; Ying X; Kang T
Biomed Chromatogr; 2016 Feb; 30(2):111-6. PubMed ID: 26031900
[TBL] [Abstract][Full Text] [Related]
7. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
8. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
[TBL] [Abstract][Full Text] [Related]
11. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
13. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Dufek MB; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
[TBL] [Abstract][Full Text] [Related]
14. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on the excretion of vitexin-4''-O-glucoside in mice after oral and intravenous administration by using HPLC.
Cai S; Chen Y; Zhang W; Ying X
Biomed Chromatogr; 2013 Nov; 27(11):1375-9. PubMed ID: 23760836
[TBL] [Abstract][Full Text] [Related]
18. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects.
Choi YH; Kim SG; Lee MG
J Pharm Sci; 2006 Nov; 95(11):2543-52. PubMed ID: 16937336
[TBL] [Abstract][Full Text] [Related]
19. Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats.
Chang-Liao WL; Chien CF; Lin LC; Tsai TH
J Ethnopharmacol; 2012 Jun; 141(2):668-73. PubMed ID: 21855624
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
Dufek MB; Knight BM; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
